Patients with multiple myeloma (MM) who have been fully vaccinated against COVID-19 were found to have an increased risk of breakthrough infections and related hospitalizations, signaling the need for more studies and precautions.
Fully vaccinated patients with multiple myeloma (MM) may be at an increased risk of breakthrough COVID-19 infections and hospitalization associated with breakthrough infection compared with patients without cancer, according to findings og a recent study.
The pattern established in the cohort study, which was published in JAMA Network Open, remained even after the investigators conducted propensity score matching for demographics, adverse socioeconomic determinants of health, transplant surgeries, comorbidities, types of vaccine, and medications (HR, 1.34; 95% CI, 1.06-1.69).
“These findings raise consideration for the development and implementation of enhanced mitigation strategies and the need for studies to evaluate the timing and impact of vaccine boosters in this unique, immunosuppressed population,” wrote the investigators.
Data from the beginning of the pandemic when vaccines were unavailable had showed an increased risk of COVID-19 infection and severe outcomes among patients with MM. Although recent studies showed a low rate of seroconversion after patients with MM and other hematological malignant neoplasms received a messenger RNA vaccine against COVID-19, the risk and outcomes of breakthrough infections among the vaccinated MM population are unknown.
The investigators used the TriNetX Analytics network platform to obtain patient electronic health records (EHRs) from 63 health care organizations in the United States, containing data on 507,288 patients, 1182 of whom had MM. The patients had to have a medical encounter with a health care organization since December 1, 2020; have evidence of full vaccination between December 1, 2020, and October 8, 2022; and have no history of COVID-19 infection.
The mean (SD) age was 68.0 (11.6) years for the MM group and 51.3 (20.8) years for the noncancer group. About 60% of the entire cohort was White. Among the patients with MM, 33.8% had monoclonal gammopathy of undetermined significance (MGUS), 11.7% were in relapse, 88.7% had never been in remission, 60.0% received chemotherapy, 50.3% received targeted therapy, 12.1% had radiation therapy, and 26.6% had received stem cell transplants.
The overall risk of breakthrough infection was 15.4% in the MM population compared with 3.9% in the noncancer population. The estimated probability of hospitalization by October 8, 2021, was 34.4% for the 181 patients with MM who had a breakthrough infection, significantly higher than that for a group of matched patients without cancer and without a breakthrough infection (4.5%; HR, 15.9; 95% CI, 6.2-40.3).
Among the patients with MM who experienced a breakthrough infection, 34.8% had MGUS, 15.5% were in relapse, 86.6% had never achieved remission, 64.2% had chemotherapy, 54.3% had targeted therapy, 11.2% had radiation therapy, and 27.8% had a stem cell transplant.
“Despite the limitations inherent to observational analysis based on patient EHRs, our study leveraged a federated nationwide and real-time patient EHR database that allowed us to electronically monitor the risks and outcomes of vaccine breakthrough infections in a real-world vulnerable population,” the investigators noted.
Reference
Wang L, Berger NA, Xu R. Risks of SARS-CoV-2 breakthrough infection and hospitalization in fully vaccinated patients with multiple myeloma. JAMA Netw Open. 2021;4(11):e2137575. doi:10.1001/jamanetworkopen.2021.37575
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Symptom Documentation Differences in Acute Cancer Care Suggest Sociodemographic Disparities
April 22nd 2025Researchers are calling for more targeted efforts to improve health equity after a new analysis revealed that cancer symptom documentation and burden vary across certain demographics.
Read More